Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Maaike Emmelot"'
Autor:
Terry, Podoll, Paul G, Pearson, Allard, Kaptein, Jerry, Evarts, Gerjan, de Bruin, Maaike, Emmelot-van Hoek, Anouk, de Jong, Bart, van Lith, Hao, Sun, Stephen, Byard, Adrian, Fretland, Niels, Hoogenboom, Tjeerd, Barf, J Greg, Slatter
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 384:173-186
Acalabrutinib is a covalent Bruton tyrosine kinase (BTK) inhibitor approved for relapsed/refractory mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. A major metabolite of acalabrutinib (M27, ACP-5862) was observed in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5b51ca94d968a8dbd551ff1f2f6f4a3
https://doi.org/10.1124/jpet.122.001116
https://doi.org/10.1124/jpet.122.001116
Autor:
Maaike Emmelot, Dennis Demont, Edwin de Zwart, Allard Kaptein, Bas van de Kar, Saskia Verkaik, Tjeerd Barf, Niels Hoogenboom
Publikováno v:
Bioorganicmedicinal chemistry letters. 52
Epidermal growth factor receptor (EGFR) inhibitors have clinical utility in the treatment of non-small cell lung cancer (NSCLC) patients. Despite encouraging clinical efficacy with these agents, many patients develop resistance due to sensitizing (or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a72f1b085718bd2e802ea453e3c644f6
https://pubmed.ncbi.nlm.nih.gov/34624491
https://pubmed.ncbi.nlm.nih.gov/34624491
Autor:
Bart Van Lith, Niels Hoogenboom, Gerjan de Bruin, J. Greg Slatter, Terry Podoll, Anouk de Jong, Maaike Emmelot-van Hoek, Tjeerd Barf, Joseph A. Ware, Allard Kaptein
Publikováno v:
Cancer Research. 79:2194-2194
Acalabrutinib is a potent and highly selective, oral covalent inhibitor of Bruton tyrosine kinase (BTK) that received accelerated approval for relapsed/refractory mantle cell lymphoma by the United States Food and Drug Administration in October 2017.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c0bab7eb2ca459c561fa2da3c05018f
https://doi.org/10.1158/1538-7445.am2019-2194
https://doi.org/10.1158/1538-7445.am2019-2194
Autor:
Diana Mittag, Bas van de Kar, Tjeerd Barf, Dennis Demont, Todd Covey, Anouk de Jong, Gerjan de Bruin, Maaike Emmelot-van Hoek, Allard Kaptein, Michael Gulrajani
Publikováno v:
Blood. 132:1871-1871
Background: Bruton tyrosine kinase (BTK) is a validated target for B-cell malignancies. The BTK inhibitor ibrutinib was approved in chronic lymphocytic leukemia, mantle cell lymphoma (MCL), and Waldenstrom macroglobulinemia. Acalabrutinib is a potent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa413fa2cecf7c801f1a71ecd94490aa
https://doi.org/10.1182/blood-2018-99-109973
https://doi.org/10.1182/blood-2018-99-109973
Autor:
Kaptein, Allard, de Bruin, Gerjan, Hoek, Maaike Emmelot-van, van de Kar, Bas, de Jong, Anouk, Gulrajani, Michael, Demont, Dennis, Covey, Todd, Mittag, Diana, Barf, Tjeerd
Publikováno v:
In Clinical Lymphoma, Myeloma and Leukemia September 2019 19 Supplement 1:S316-S317